By Ben LevisohnInvestors love biotech stocks, but heading into July, Amgen (AMGN) was unloved, especially compared to its other biotech giants like Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Biogen (BIIB). No longer. Shares of Amgen have jumped nearly 6% after reporting better than forecast earnings and raising its guidance. UBS analyst Matthew Roden has the details:
Amgen reported another strong […]
Capitalize on Comeback Stories in Micro-Cap Biotech StocksCompanies / BioTechJun 17, 2015 – 09:55 PM GMTBy: TLSReportThe list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors […]
View All3 Potent Biotech Stocks That Could Pop on EarningsLike golf, investing in biotech stocks can be cruel game. As Michael A. Gayed explains, the pricing dynamic of individual biotech stocks will often follow the perceived successes — or failures — of drug trials and the multiple approval procedures enforced by regulatory agencies.Source: ©iStock.com/twilightproductionsThis Wild West mentality is primarily the […]
U.S. stocks were a mixed bag on Tuesday, with the Dow ending lower after a handful of uninspiring earnings reports while the Nasdaq closed near a record high following a proposed biotech merger.Travelers, DuPont and IBM shares weighed on the Dow Jones industrial average. DuPont reported lower sales in all of its businesses and said a strong dollar would take […]
Traders work on the floor of the New York Stock Exchange April 20, 2015.Reuters/Brendan McDermid n”>(Reuters) – U.S. stocks were mixed on Tuesday, with the Dow industrials pulled down by a handful of uninspiring earnings reports, while the Nasdaq was pushed higher by a proposed biotech merger.Travelers, DuPont and IBM shares weighed on the Dow. DuPont reported lower sales in […]
Source: Flickr user Ali T.Clinical stage biotech stocks can have nausea-inspiring pops-and-drops tied to news, and that makes them suitable for only the most risk-tolerant of investors. However, investors willing to accept the risk of loss can reap substantial rewards if promising pipeline drugs like Xoma Corp ‘s gevokizumab succeed in clinical trials. Since Xoma could begin reporting late stage […]
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
By iCELL News on February 20, 2015 · Investing
SummaryIn 2015, the focus of the checkpoint inhibitor space will be on additional cancer types, beyond melanoma, as well as on collaborations and combinations.
The financial resources needed to develop an advantage in the anti-PD-1/PD-L1 space are now beyond the reach of most smaller […]
Why Neuralstem, Inc. Shares Surged Higher
By iCELL News on February 20, 2015 · Investing
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.What: Shares of Neuralstem, Inc (NYSEMKT: CUR ) jumped by as much as 9.6% today after Brean […]
This week Jim Cramer has been highlighting the hottest biotech stocks for 2015 as a part of his series “Biotech, the Next Generation.”One of the best performing biotechs for 2014 was the orphan drug company PTC Therapeutics, which rallied 205 percent last year. Shire PLC recently acquired NPS Pharmaceuticals at a 51 percent premium to where it was trading before.This […]
It was generally a good year for biotechnology stocks, but the sector remains a risky one. Below are 20 biotechnology companies that lost more than 70% of their value in 2014. (Click here for a list of the best performers.)There aren’t many lessons here. Tolstoy said that happy families are all alike, and but every unhappy family is unhappy in […]
